To the Editor:
Systemic anaplastic large cell lymphoma (sALCL) encompasses two distinct clinical entities of T-cell non-Hodgkin lymphoma: anaplastic lymphoma kinase-positive (ALK+) ALCL and ALK-negative (ALK−) ALCL. These entities are characterized by either the presence or absence of an ALK translocation. It has been reported that ALK+ ALCL has a better prognosis compared to ALK−, with a 5-year overall survival (OS) of 70–80% versus 40–60%, respectively, [1,2,3]. Furthermore, more than 30% of ALK+ ALCL patients relapse [4, 5]. Despite the distinction between the two sALCL subtypes, frontline treatment for adults is similar and is based on CHOP or CHOEP, instead pediatric ALCL patients are mainly treated following the ALCL99 protocol [6,7,8]. Whilst high-throughput genomic studies in sALCL have shown recurrent genetic alterations, their association with outcome has not been fully investigated [9,10,11,12,13].
In this study, the mutational landscape of sALCL patient tumors was investigated to discover potential biomarkers that may improve risk stratification and patient management.
A cohort of 82 sALCL patient tumors (47 ALK+ and 35 ALK−) and 6 ALCL cell lines (4 ALK+, 2 ALK−) (Table S1) were subjected to deep targeted next-generation sequencing analyzing the whole coding regions of 275 cancer related genes (Table S2). The average depth achieved across all the samples sequenced was ~2000×. Sequencing data are available at Sequence Read Archive (https://www.ncbi.nlm.nih.gov/sra/, SRA identifier PRJNA602225).
Male subjects were predominant in both subgroups of our cohort, 57.4% in ALK+ versus 67.6% in ALK−. ALK+ patients were significantly younger than ALK− patients with an average age of 22.7 (3–61) and 55.2 (27–81) years, respectively. ALK+ ALCL patients had a longer survival than ALK− ALCL with a 7-year OS of 77.6% and 46.7%, respectively, and with 7-year progression free survival (PFS) being comparable at 58.7% for ALK+ and 44.1% for ALK− patients (Fig. S1). The first line of treatment for all the adult patients was systemic chemotherapy, and most of the childhood ALK+ ALCL patients (80%) were treated following the ALCL99 or ALCL98 protocols. Although ALK+ patients have a longer OS, more than 30% relapsed after first-line treatment. Among the 275 genes analyzed, we identified 148 (54%) genes harboring at least one mutation throughout the entire cohort; 132 genes among the patients and 43 among the cell lines, with 27 genes in common (Fig. S2, Table S3). Overall, 72 out of 82 (88%) patients carried at least one mutation within the genes analyzed. We detected an average of 4.2 mutations per patient in ALK− ALCL and an average of 2.7 in ALK+ ALCL. The most recurrently mutated gene in the entire cohort was TP53 found in 16% of sALCL patients (11% ALK+, 23% ALK− and in all ALK+ cell lines). Interestingly, for the ALK+ group, mutated TP53 was more frequent in young patients (p < 0.04). LRP1B was prevalently mutated in ALK+ patients (19%) and in three cell lines. STAT3 and JAK1 were mutated solely in ALK− ALCL, both with a prevalence of 26%, and were the most mutated genes in this group (Fig. 1a). Recurrent mutations were detected in epigenetic modifier genes also recently reported to be frequently mutated in BIA-ALCL . KMT2D and TET2 were found mutated in ALCL patients regardless of ALK status and EP300 and KMT2C only in ALK+ patients. Pathway enrichment analysis showed a significant enrichment in mutated genes involved in JAK/STAT (p < 0.003) and PI3K/AKT signaling pathways (p < 0.02) for ALK− ALCL compared with ALK+ ALCL (Fig. 1b). We investigated possible correlations between the existence of mutations in the most mutated genes and the clinical characteristics of our cohort. Poor prognostic outcome was defined as patients meeting at least one of the following criteria: deceased, unresponsive to treatment and/or disease relapse. The most recurrently mutated genes in the poor prognostic sub-cohort independent of ALK status were TP53 (27%), STAT3 (24%), EPHA5 (16%), JAK1 (16%), PRDM1 (13.5%), LRP1B (11%) and KMT2D (11%). Considering only refractory/relapsed ALCL patients, mutations within TP53 (28%) and EPHA5 (19%) were the most common (Table S4). In relation to the prognosis, ALK+ patients did not show any significant difference in the signaling pathways affected by mutations. On the contrary, the JAK/STAT (p < 0.005) and PI3K/AKT pathways (p < 0.036) were enriched in ALK− ALCL patients with an inferior outcome (Fig. 1b). Pathogenetic variants of STAT3 were detected in 9/35 (26%) of ALK− ALCL patients. Mutations were located mainly within the SH2 domain (S614R, E616G, Y640F, N647I, K658delinsNM and D661V) and in one case within the DNA binding domain (C426R). Mutated JAK1 was detected in 9/35 (26%) of ALK− ALCL patients and of those, 6/9 were at the hotspot codon 1097 (G1097D/F/N/S) (Fig. 1d). For four patients, JAK1 was mutated together with STAT3, thereby emphasizing the importance of the JAK/STAT signaling axis. To evaluate the prognostic value of mutations in the JAK/STAT pathway, we performed Cox regression analysis and showed that ALK− ALCL patients harboring STAT3 and/or JAK1 mutation have a shorter OS (hazard ratio [HR] = 2.8; 95% confidence interval [CI], 1.1–7.1, p < 0.03) (Fig. S3A). Furthermore, the prognostic value of the most mutated genes in ALK− ALCL: STAT3 (9/35), JAK1 (9/35), TP53 (8/35) and KMT2D (7/35) were investigated. Cox regression analysis showed that patients with STAT3 mutations have a significantly shorter OS compared to those with wild-type STAT3 (HR = 4.1; 95% CI, 1.56–10.71, p < 0.002) (Fig. 1c). In addition, while JAK1 and KMT2D mutations did not significantly correlate with OS (p < 0.2 and p < 0.3, respectively), TP53 mutations clearly displayed the correlation (p < 0.01) (Fig. S3B–D). To further confirm that mutations in STAT3 are associated with shorter OS, we applied Akaike’s informative criteria model to the four aforementioned genes. STAT3 mutations were found to be the best predictor of OS in ALK− ALCL (Table S5). Moreover, no significant differences were found between mutation status of these genes with age, gender, disease stage, eastern cooperative oncology group performance status or age-adjusted international prognostic index (AA-IPI). As expected [9, 13, 15], expression of p-STAT3 (Y705) was detected at a high level in all ALK− ALCL patients harboring STAT3 mutations, although low/medium expression of p-STAT3 was also detected in STAT3 wild-type patient tumors (Fig. S4, Table S6). Mutations in the LRP1B gene were detected in 12/82 (15%) of sALCL patients (19% ALK+ and 9% ALK−) and three cell lines. Since LRP1B was the most recurrently altered gene in ALK+ ALCL, we assessed its possible association with outcome, but no differences were found between mutated and nonmutated patients.
To investigate somatic mutations with a possible role in disease relapse, we sequenced paired diagnostic and relapse samples available for four patients (1 ALK+ and 3 ALK−) (Fig. 2a). Two different acquired mutations in EPHA5 were detected in each of the two relapse samples (patient tumors ALK+ 1R and HK-10R): a stop codon at S566 and a glycine–valine change at residue 723. In the latter patient (HK-10), identification of mutated EPHA5 appears to be the result of the emergence of a new malignant clone, harboring novel mutations in several other genes consistently with a similar variant allele frequency (Fig. 2b). Interestingly, EPHA5 was also found to be the second most mutated gene in relapsed/refractory patients in the entire cohort (Table S4B). Three out of four patients harbored mutated TP53 both at diagnosis and at relapse (Fig. 2b). As TP53 is the most recurrent gene mutated in our cohort and the most mutated gene in relapsed patients (Table S4B), we investigated its possible association with the treatment outcome for all ALCL patients regardless of ALK status. Nearly all mutations in TP53 were detected in the DNA binding domain except for L344P in the TET domain for one patient (Fig. 2d). sALCL patients harboring TP53 mutations have a shorter PFS compared to those with the wild-type gene (HR = 3.3; 95% CI, 1.59–6.87, p < 0.0007) (Fig. 2c). These data, together with the diagnosis versus relapse analysis, suggest that TP53 mutations may confer resistance to chemotherapy. Moreover, mutations in TP53 were the most common genetic events on re-analysis of publicly available datasets (Table S7) [9, 11].
Losses at the genomic regions that encompass TP53 and PRDM1 genes have been shown to be the most common lesions in sALCL with a clinical implication . PRDM1 mutations were detected in five patients, with three of these co-occurring with TP53 mutations and all five patients being categorized within the poor prognostic sub-group. These data confirm the correlation between TP53 and PRDM1 gene mutations, thereby demonstrating either copy number loss or concomitant mutations are mechanisms which have the potential to alter p53 and PRDM1 pathways activity.
In summary, within one of the largest cohort of 82 sALCL patients, we provide robust information on the genetic spectrum of genes either solely mutated in ALK− ALCL (STAT3, JAK1) or across the whole spectrum of ALCL (TP53, LRP1B, EPHA5, KMT2D). In addition, we describe novel biomarkers for predicting treatment outcome reporting an association between mutated STAT3 and TP53 with an inferior outcome, in the former case in ALK− disease and in the latter case all sALCL independent of ALK status. Finally, this mutational landscape provides further candidate genes that deserve consideration for their possible role in the patient outcome, such as EPHA5, KMT2D, PRDM1 and SOCS1.
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496–504. http://www.ncbi.nlm.nih.gov/pubmed/18385450.
Janikova A, Chloupkova R, Campr V, Klener P, Hamouzova J, Belada D, et al. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol. 2019. http://link.springer.com/10.1007/s00277-019-03694-y.
Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;2:17–25. https://pubmed.ncbi.nlm.nih.gov/25869285/.
Brugières L, Deley MC Le, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe MJ, Robert A, et al. CD30+ anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French Society of Pediatric Oncology. Blood. 1998;92:3591–8.
Mussolin L, Damm-Welk C, Pillon M, Zimmermann M, Franceschetto G, Pulford K, et al. Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis. Leukemia. 2013;27:416–22. http://www.ncbi.nlm.nih.gov/pubmed/22907048.
Morel A, Brière J, Lamant L, Loschi M, Haioun C, Delarue R, et al. Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: a LYSA/SFGM-TC study. Eur J Cancer. 2017;83:146–53.
Wrobel G, Mauguen A, Rosolen A, Reiter A, Williams D, Horibe K, et al. Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: Report of the ALCL99 randomised trial. Pediatr Blood Cancer. 2011;56:1071–7. http://www.ncbi.nlm.nih.gov/pubmed/21280197.
Prokoph N, Larose H, Lim MS, Burke GAA, Turner SD. Treatment options for paediatric anaplastic large cell lymphoma (ALCL): current standard and beyond. Cancers. 2018;10:1–18.
Crescenzo R, Abate F, Lasorsa E, Tabbo’ F, Gaudiano M, Chiesa N, et al. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27:516–32. https://linkinghub.elsevier.com/retrieve/pii/S153561081500094X.
Larose H, Prokoph N, Matthews JD, Schlederer M, Högler S, Alsulami AF, et al. Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica. 2020. http://www.haematologica.org/lookup/doi/10.3324/haematol.2019.238766.
Song TL, Nairismägi ML, Laurensia Y, Lim JQ, Tan J, Li ZM, et al. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma. Blood. 2018;132:1146–58.
Boi M, Rinaldi A, Kwee I, Bonetti P, Todaro M, Tabbò F, et al. PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood. 2013;122:2683–93.
Andersson EI, Brück O, Braun T, Mannisto S, Saikko L, Lagström S, et al. STAT3 mutation is associated with STAT3 activation in CD30+ ALK− ALCL. Cancers. 2020;12:702. https://www.mdpi.com/2072-6694/12/3/702.
Laurent C, Nicolae A, Laurent C, Le Bras F, Haioun C, Fataccioli V, et al. Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant–associated ALCL. Blood. 2020;135:360–70.
Shen J, Li S, Medeiros LJ, Lin P, Wang SA, Tang G, et al. PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. Mod Pathol. 2020;33:324–33. https://www.nature.com/articles/s41379-019-0336-3.
This project has received funding from the European Union’s Horizon 2020 Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) under grant agreement no. 675712. The project was also supported by Czech Science Foundation (GACR), GA19-15737S and junior project no. 19-23424Y, the MEYS CZ project CEITEC 2020 (LQ1601) and project MH CZ-DRO (FNBr, 65269705). We acknowledge the CF Genomics CEITEC MU supported by the NCMG research infrastructure (LM2018132 funded by MEYS CR) and Core Facility Bioinformatics of CEITEC MU for their support with scientific data presented here. We thank Vasileios Bikos and Stephen Paul Ducray for the support and advice. We acknowledge the different biobanks for collecting the samples and providing access to them: the CCLG Tissue Bank and contributing CCLG Centres, members of the ECMC Paediatric Network, the Czech National Lymphoma Registry (NiHiL, NCT 03199066), University Hospital Brno (grant no. NV18-03-00054) and University Hospital Hradec Kralove (Project BBMRI-CZ, no.: EF16 013/0001674).
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Lobello, C., Tichy, B., Bystry, V. et al. STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma. Leukemia 35, 1500–1505 (2021). https://doi.org/10.1038/s41375-020-01093-1